R&D Partner Content 6th GxP Cloud Compliance Summit 2025 Advancing AI Advancing AI Validation, Risk Management, and Cloud Security to Ensure GxP Cloud Compliance
R&D Partner Content Innovation in Psychosis Therapeutics Summit Join leaders at the Innovation in Psychosis Therapeutics Summit to revolutionize psychosis treatment
R&D Partner Content 4th ALS Drug Development Summit Join 200+ experts at the 4th ALS Summit to advance biomarkers, targets, and trials for ALS & FTD
R&D Partner Content London Biotechnology Show London Biotechnology Show Levels Up with Industry Pioneers in Exhibitor Lineup, Hosted Buyer Programme
R&D Partner Content 2nd GLP-1-Based Therapeutics Summit If you thought that 2024 was the year for GLP-1 Agonists, then hold on for 2025!
R&D Partner Content 5th Inner Ear Disorders Therapeutics Summit Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clin
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
